What are engineered antibodies used for?
Click to see answer
As tumor therapeutics.
Click to see question
What are engineered antibodies used for?
As tumor therapeutics.
What is the primary application of engineered antibodies in medicine?
To treat tumors.
Why is HIV-1 Env a difficult target for antibodies?
Due to low density Env expression and high antigenic variability.
What is a major roadblock for the evolution of broadly neutralizing antibodies (bnAbs)?
The reasons for their limited elicitation in individuals are not fully understood.
What are broadly neutralizing antibodies (bnAbs)?
Potent antibodies that protect against HIV-1 in vitro and in vivo.
What contributes to the structural challenges of HIV-1 Env?
Structural flexibility and conformational shielding.
What are broadly neutralizing antibodies (bnAbs)?
Antibodies that can neutralize a wide range of viral strains.
Why are potent bnAbs only elicited in a small fraction of individuals?
The specific reasons are unclear and may involve various factors.
What are broadly neutralizing antibodies (bnAbs)?
Potent antibodies that protect against HIV-1.
In which viral diseases have bnAbs been discovered?
HIV, Influenza, Norovirus, Hepatitis C Virus, CMV, Ebola, Adenovirus.
What range of HIV-1 subtypes are bnAbs active against?
A wide range.
What factors may influence the elicitation of bnAbs?
Host, viral, or disease factors could be decisive.
What are gp41 stumps and gp120 shedding?
Features of HIV-1 Env that complicate immune recognition.
How do bnAbs perform in studies?
They protect in vitro and in animal studies in vivo.
What is the focus of current efforts regarding bnAbs?
To develop bnAb-based vaccines for various infections.
How does the immune system perceive HIV-1 Env?
It sees a range of Env products, including alternate closed and minimally opened conformations.
Are only distinct Env proteins capable of inducing bnAb activity?
It is unclear if only distinct Env proteins can induce bnAb activity.
What do bnAbs target on the HIV-1 virus?
The intact, closed trimer via multiple sites.
What range of HIV-1 subtypes are bnAbs active against?
A wide range of HIV-1 subtypes.
What is a characteristic feature of broadly neutralizing antibodies (bNAbs)?
They frequently have long CDRH3 regions.
What are broadly neutralizing antibodies (bnAbs)?
Potent antibodies that protect against HIV-1 in vitro and in vivo.
Which infections have the most advanced bnAb-based vaccine efforts?
Influenza, HIV, and Norovirus.
Why is the neutralization relevant closed trimer of HIV-1 Env not stable?
Due to its structural characteristics and variability.
What factors can potentially be engaged to develop bnAb vaccines?
Host factors, immune environment, and viral/antigen factors.
What do bnAbs target on the HIV-1 virus?
The intact, closed trimer via multiple sites.
What is the range of somatic mutations found in CDR regions of bNAbs?
10 - 30%.
What are bnAbs?
Broadly neutralizing antibodies that target multiple epitopes on the HIV-1 envelope trimer.
Do bnAbs develop in all patients?
No, they only develop in some patients.
What is the primary focus of the document regarding therapeutic antibodies?
Nomenclature of therapeutic antibodies.
How are bnAbs considered in the context of HIV?
As therapeutics.
How do bnAbs perform in studies?
They protect in vitro and in animal studies in vivo.
Do bnAbs develop in all patients?
No, they only develop in some patients.
How do somatic mutations in bNAbs compare to non-HIV IgG?
Non-HIV IgG carry 15 – 20 VH-gene somatic mutations, while potent bNAbs carry 40 – 100 VH-gene mutations.
What was the outcome of the first large-scale human trial (AMP Study) for bnAbs?
It was not successful.
Why is nomenclature important in the context of therapeutic antibodies?
It helps in standardizing the naming conventions for better communication and understanding in the field.
Against how many HIV-1 subtypes are bnAbs active?
A wide range of HIV-1 subtypes.
What are some specific sites that bnAbs target?
V3 Glycan, V1V2 Glycan, CD4bs, Interface, Fusion peptide, MPER.
What type of virus is the Dengue virus?
Flavivirus, ss RNA(+).
What questions arise regarding the high mutation rate in bNAbs?
What triggers this? Is the high mutation rate needed for function? How can this be triggered by vaccination?
What does the nomenclature of therapeutic antibodies typically include?
It includes prefixes, infixes, and suffixes that indicate the source, type, and target of the antibody.
What have animal studies shown regarding bnAbs?
They have been successful in demonstrating the potential of bnAbs as therapeutics.
What do bnAbs target on the HIV-1 virus?
The intact, closed trimer via multiple sites.
How is the Dengue virus primarily transmitted?
Through mosquito-borne virus infection.
What is a common suffix used in the nomenclature of therapeutic antibodies?
The suffix '-mab' indicates that the molecule is a monoclonal antibody.
What unusual features do broadly neutralizing HIV-1 antibodies have?
They have an unusually high degree of somatic mutations in both CDR and FWR regions.
What is the current focus of the field regarding bnAb induction?
To define immunogens that elicit bnAbs and identify roadblocks to bnAb induction.
Do bnAbs develop in all patients?
No, they only develop in some patients.
What is the estimated number of Dengue infections per year?
50 to 100 million.
What does the prefix in therapeutic antibody nomenclature signify?
The prefix often indicates the species from which the antibody is derived.
What is a promising finding related to bnAb treatment?
It can delay or reduce virus replication.
How many serotypes of the Dengue virus exist?
Four serotypes.
What has been the success of bnAb induction by vaccination so far?
There has been no success in inducing bnAbs by vaccination thus far.
How can novel antibodies and immunogens be defined?
Novel antibodies and immunogens can be defined through their unique structures and functions that elicit specific immune responses.
What percentage of annual Dengue infections are asymptomatic?
95%.
What type of antibodies have been discovered in the context of bnAbs?
Highly potent and broad antibodies.
What is the significance of tracing the viral antigen that triggered bnAb?
Tracing the viral antigen helps in understanding the immune response and the development of broadly neutralizing antibodies.
Does infection with one serotype of Dengue provide protection against others?
No, it does not provide protection.
What do bnAbs target on the HIV-1 virus?
Multiple epitopes on the HIV-1 envelope trimer.
What does bnAb cloning involve?
bnAb cloning involves isolating and characterizing antibodies that can neutralize a wide range of viral strains.
What serious complications are associated with secondary Dengue infections?
Dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS).
What is a key factor influencing the effectiveness of antiviral antibodies?
Affinity.
What have small-scale human studies shown about bnAbs?
They have shown promising findings.
What is biochemical characterization in the context of bnAbs?
Biochemical characterization involves analyzing the properties and interactions of bnAbs at a molecular level.
What is the sequence variation percentage among the four Dengue serotypes?
30 to 35%.
Why is epitope accessibility important for antiviral antibodies?
It affects neutralization and effector functions.
What is functional characterization of bnAbs?
Functional characterization assesses the ability of bnAbs to neutralize viruses and their mechanisms of action.
What does epitope density refer to in the context of antiviral antibodies?
The concentration of epitopes available for antibody binding.
What is a germline ancestor in the context of bnAbs?
A germline ancestor refers to the original antibody structure from which a broadly neutralizing antibody evolves.
What are the desired features of antiviral antibodies?
Long half-life, low immunogenicity, and no off-target effects.
Why is it important to design immunogens that bind to the germline ancestor?
Designing immunogens that bind to the germline ancestor can enhance the elicitation of bnAbs during vaccination.
How does differential glycosylation affect antiviral antibodies?
It influences Fc epitope accessibility and antibody function.
What is the goal of creating therapeutic bnAbs?
The goal is to develop antibodies that can effectively neutralize a wide range of viral infections for therapeutic use.
What is the significance of epitope accessibility during viral entry?
It is crucial for effective neutralization by antibodies.
